Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility

Related Experiment Video

Updated: Jul 16, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Alice Bjerregaard Larsen1, Mikkel Wandahl Pedersen, Marie-Thérése Stockhausen

  • 1Department of Radiation Biology, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.

Molecular Cancer Research : MCR
|March 22, 2007
PubMed

Insights

Epidermal growth factor receptor (EGFR) activation upregulates EphA2 expression in cancer cells, impacting tumor metastasis. EphA2 plays a functional role in EGFR-driven cancer cell motility.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • EphA2 overexpression is linked to cancer metastasis and angiogenesis.
  • Epidermal growth factor receptor (EGFR) signaling is crucial in many cancers.

Purpose of the Study:

  • To investigate the relationship between EGFR signaling and EphA2 expression in human cancer cells.
  • To elucidate the functional role of EphA2 in EGFR-driven cancer cell motility.

Main Methods:

  • Utilized mammalian cell lines (A431, HN5) with activated EGFR and EGFRvIII.
  • Investigated EphA2 promoter activity and downstream signaling pathways (MAPK/ERK).
  • Performed co-immunoprecipitation and small interfering RNA (siRNA) knockdown experiments.

Main Results:

  • Activated EGFR and EGFRvIII induce EphA2 expression, partially via MAPK/ERK signaling and direct promoter effects.
  • EGFR and EphA2 colocalize at the plasma membrane, with EphA2 interacting with activated EGFR/EGFRvIII.
  • EphA2 activation and knockdown inhibit EGF-induced cell motility in EGFR-overexpressing cancer cells.

Conclusions:

  • EGFR signaling directly regulates EphA2 expression in cancer cells.
  • EphA2 is functionally involved in EGFR-mediated cancer cell migration, suggesting therapeutic potential.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration08:55

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration

Published on: March 17, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...